|
|
||||||||
1From the Department of Ocular Immunology, Institute of Ophthalmology, London, United Kingdom; and the 2Moorfields Eye Hospital, London, United Kingdom.
| Abstract |
|---|
|
|
|---|
METHODS. C57BL6 donor corneas were transplanted into naive A/J mice, A/J mice sensitized to short ragweed (SRW) pollen by intraperitoneal injection and then challenged with topical SRW to induce allergic conjunctivitis (Sens+Chall+), and A/J mice sensitized to SRW and challenged with topical PBS (Sens+Chall–). Syngeneic grafts were also performed in eyes with allergic conjunctivitis. Graft survival and infiltrating cell phenotype in rejected grafts were compared between groups.
RESULTS. Mice with allergic conjunctivitis (Sens+Chall+) rejected corneal allografts significantly more quickly than naive mice. Syngeneic grafts in allergic eyes survived indefinitely. The rate of rejection in Sens+Chall– mice was similar to that in naive mice. There were no significant differences, between groups, in the numbers of infiltrating CD4+ cells, CD8+ cells, and macrophages at the time of graft rejection. Eosinophils were seldom observed in rejected grafts in naive and Sens+Chall– mice but were observed consistently in Sens+Chall+ eyes. Eosinophils were also found consistently in the ciliary body of Sens+Chall+ eyes at the time of graft rejection.
CONCLUSIONS. Active allergic conjunctivitis at the time of transplantation accelerates corneal allograft rejection. Local conjunctival inflammation is an important factor in accelerating rejection.
The aim of this study was to investigate the effect of a specific type of perioperative ocular inflammation, allergic conjunctivitis, on corneal allograft rejection. Allergic conjunctivitis is important in the context of corneal transplantation for 2 reasons. First, it is the most prevalent form of ocular inflammation in general.2 It may actually be overrepresented in corneal transplant patients given the association between allergic eye disease and keratoconus,3 4 the usual indication for corneal transplantation.5 6 Second, atopy is associated with a skewing of the T-helper cell immune responses toward Th2.7 8 Alterations in Th1/Th2 bias may influence the immune response to an allograft.
Convergent studies have identified the CD4 (T-helper [Th]) cell as the key effector cell in corneal allograft rejection.9 10 Activated Th cells secrete cytokines, which in turn activate and recruit effector cells. Th cells may be classified as Th1 (IL-2, IFN-
) or Th2 (IL-4, IL-5, IL-10), depending on the profile of their cytokine secretion. Traditionally, allograft rejection has been thought to be a Th1-mediated process.11 This is largely true of unmodified corneal transplantation.12 13 However, Th2 and Th1 cells cross-regulate each other. It has been hypothesized that by enhancing the Th2 response, the Th1 response would be attenuated and graft tolerance would be achieved.14 Experimental strategies to deviate the immune response toward Th2 in cardiac allografts have had mixed results in terms of allograft survival.15 16 17 However, one thing has become clear: a Th2-dominant response to alloantigen is capable of graft destruction, possibly via novel effector mechanisms such as eosinophilic infiltration.18
Prior sensitization to allergen has been shown to induce an increased Th2 response to alloantigen. As in other types of allograft, the effects of this on corneal allograft survival have been mixed. In a model of high-risk corneal transplantation to a vascularized recipient bed, Th2 bias improved graft survival.19 However, in a model of normal risk transplantation, accelerated corneal allograft rejection was found in patients with allergic conjunctivitis, and this was attributed to the Th2 bias induced by systemic sensitization with allergen.20 Our study examines the effect of perioperative allergic ocular inflammation on allograft survival and on the composition of the inflammatory infiltrate during rejection.
| Methods |
|---|
|
|
|---|
|
Induction of Corneal Inflammation
To induce corneal inflammation, four 11.0 nylon sutures were placed in the paracentral corneal stroma of A/J mice and were removed after 1 week.
Transplantation Technique and Diagnosis of Rejection
The technique for corneal transplantation was as previously reported.22 Mice were anesthetized with intraperitoneal fentanyl fluanisone and midazolam. All grafts were performed in the right eye. A 2.5-mm donor button was sutured into a 2.0-mm recipient corneal bed with a continuous 11–0 nylon suture. At the end of the procedure, tarsorrhaphy was performed. This was opened after 48 hours; eyes with infection, hemorrhage or cataract were excluded. Thereafter, the eyes were examined three times weekly under brief inhalational isoflurane anesthesia, and the graft graded as follows: 0 = completely transparent cornea; 1 = minimal corneal opacity, but iris vessels easily visible; 2 = moderate corneal opacity, iris vessels still visible; 3 = moderate corneal opacity, only pupil margin is visible; 4 = complete corneal opacity, pupil not visible.
Corneal sutures were removed at 7 days. Corneal graft rejection was diagnosed when the corneal clarity score increased to 3 in a graft previously transparent after surgery.
Immunohistochemistry
On diagnosis of rejection, mice were killed and the whole eye was enucleated. The eye was embedded in optimal cutting temperature compound (OCT; Sakura Finetek Europe BV, Zoeterwoude, The Netherlands) and was frozen on a liquid nitrogen-cooled duralumin plate. Specimens were stored at –70°C. Cryostat sections 8-µm thick were cut, and indirect frozen section immunohistochemical analysis was performed using the following primary antibodies: rat anti–mouse CD4, RM4–5 (BD Biosciences, San Jose, CA) 1:100 dilution; rat anti–mouse CD8, YTS105.18 (Serotec, Raleigh, NC) 1:100 dilution; rat anti–mouse F4/80, CI:A3–1 (Serotec) 1:300 dilution; and rat anti–mouse major basic protein (kind gift from Dr. J. Lee, Mayo Clinic, Scottsdale, AZ). Mouse anti–rat IgG1, IgG2a and IgG2b isotype controls (all from Serotec) were used at appropriate dilutions as controls. Positive-staining cells in the central cornea and the ciliary body were counted. Because rejected corneal allografts demonstrate variable thickness resulting from edema, it was not appropriate to count the number of cells per unit area. Instead, the number of positive cells throughout the full thickness of a 100x field of the central stroma of each section was counted. Cells were counted in three sections per rejected graft. At least five grafts were examined in each group. Sections of the ciliary body were imaged, and their cross-sectional areas were measured using image analysis software (Soft Imaging System GmbH, Munster, Germany). The number of positive-staining cells in each ciliary body section was counted using high magnification and expressed as cells/0.1 mm2. Cells were counted in three sections per eye. At least five eyes were examined in each group.
To study the effects of the sensitization protocol (without challenge) on the recipient cornea, we compared frozen sections from Sens+Chall– eyes with normal eyes and with eyes with suture-induced corneal inflammation. Sections were stained directly with phycoerythrin (PE)-conjugated rat anti–mouse CD11b, M1/70 (BD Biosciences), dilution 1:100, and PE-conjugated rat anti–mouse CD11c, B-ly6 (BD Biosciences), dilution 1:100. Other sections were stained with primary rat anti–mouse LYVE-1, 223322 (R&D Systems Minneapolis, MN), dilution 1:400, and then with secondary Alexa-488–conjugated donkey anti–rat antibody (Invitrogen, Carlsbad, CA). Four eyes per group were examined.
Statistical Analysis
Median graft survival time (MST) was calculated for each group, and Kaplan-Meier survival curves were constructed.23 Survival was compared using the log-rank test. The unpaired Student's t-test was used to compare numbers of graft-infiltrating leukocytes between groups. The
2 test was used to compare groups for the presence of infiltrating eosinophils. For each statistical test, P < 0.05 was defined as statistically significant.
| Results |
|---|
|
|
|---|
|
|
Survival of Isografts in Mice with Allergic Conjunctivitis
To establish whether graft failure in allergic mice was primarily caused by a specific response against alloantigens or nonspecific allergic inflammation, syngeneic corneal grafts were placed in sensitized A/J mice that were then challenged with SRW eyedrops in the graft eye to induce allergic conjunctivitis. All (100%) these syngeneic grafts survived for 60 days.
Composition of Graft Infiltrate during Acute Rejection
Phenotypes of graft-infiltrating cells were characterized using immunohistochemistry, and comparisons were made between rejected grafts in naive, Sens+Chall+, and Sens+Chall– mice. No significant differences were observed in the numbers of CD4+, CD8+, and F4/80+ cells infiltrating the grafts at the time of rejection in all groups (Fig 3) . Within each group, no significant differences were observed in the numbers of graft-infiltrating CD4+, CD8+, and F4/80+ cells.
|
|
|
|
| Discussion |
|---|
|
|
|---|
Animals in the model of allergic conjunctivitis we report underwent two interventions, either of which could in theory have influenced graft survival. The preliminary sensitization of animals to SRW has been shown by others to skew the immune response toward Th2.19 20 Subsequent challenge with topical SRW induces local ocular inflammation. It is of interest that animals sensitized to SRW but not challenged rejected allografts at a rate similar to that of naive animals. This is consistent with our finding that, after sensitization, the cornea appears normal in terms of its antigen-presenting cell (APC) and lymphatic content. Taken together, these findings suggest that local perioperative inflammation rather than any systemic effect of SRW sensitization is responsible for the increased rate of allograft rejection after perioperative allergic conjunctivitis. In other words, the presence of local perioperative inflammation confers the status of high rejection risk on the graft.
For reasons that are unclear, this finding is in contrast with the findings of Beauregard et al.,20 who report that, in their model of allergic conjunctivitis, the increased rate of allograft rejection was attributable to increased Th2 responses rather than to local inflammation. Differences in the models of allergic conjunctivitis may in part explain the variance in results: a different strain of graft recipient mouse (A/J as opposed to BALB/c) was used in the experiments we report, and the allergic conjunctivitis induction protocol differed in that we challenged the conjunctiva with SRW only once rather than throughout the posttransplantation period of observation. On one hand, the survival results in animals with active allergic conjunctivitis (Sens+Chall+) were similar in both studies. The difference lies in the groups of animals sensitized but not challenged (Sens+Chall–), and here the protocols also differed. We designed Sens+Chall+ and Sens+Chall– groups to represent, as closely as possible, the clinical picture seen in patients with allergic conjunctivitis and without active or uncontrolled disease. Therefore, our Sens+Chall– animals received one mock challenge with PBS in the corneal graft (ipsilateral) eye and nothing in the contralateral eye. Graft recipients in the study by Beauregard et al.20 received repeated mock challenges with PBS in the ipsilateral eye and repeated SRW challenges in the contralateral eye. It is not clear why SRW challenge in the contralateral eye should lead to accelerated graft rejection. One possibility is that as mice rub their eyes vigorously after challenge with SRW, inadvertent contralateral transfer of SRW occurs. This also raises the possibility that accelerated graft rejection in these models of allergic conjunctivitis may result from the mechanical effects of eye rubbing alone.
The immune response to alloantigen consists of an afferent and an efferent arm. In the afferent arm, APCs travel from the graft-bearing alloantigen to regional lymph nodes, where they are presented to T cells. Increased expression of MHC class II in the cornea has been described in experimental allergic conjunctivitis,25 raising the possibility that alloantigen recognition in the afferent limb may be enhanced in Sens+Chall+ recipients of allografts. The efferent arm culminates in infiltration and destruction of the graft by a variety of effector cells. We have shown that perioperative allergic conjunctivitis influences the effector arm of the immune response in that it is associated with an eosinophilic infiltrate during graft rejection. Graft infiltration by eosinophils has been previously described in rejected human allografts in patients with allergic conjunctivitis.26 Eosinophilic infiltration is a prominent feature of unmodified rejection in corneal and pancreatic xenotransplants.27 28 29 In animal models of skin and cardiac allotransplantation, eosinophilic infiltration is seen characteristically in Th2-biased animals.17 30
Three questions must be addressed regarding eosinophils: Are they specifically recruited to the cornea during graft rejection? Do they contribute to graft destruction? Are they responsible for the increased rate of graft rejection?
One possible route of alloreactive cell trafficking in rejection to graft stroma is by way of the surrounding conjunctiva. Another is to the graft endothelium by way of the ciliary body and iris through the anterior chamber. Eosinophils that enter the cornea and anterior chamber in allergic eyes appear to do so as part of a specific response to alloantigen, an observation supported by the absence of eosinophils in isograft recipient eyes with allergic conjunctivitis despite their presence in the conjunctiva. The capacity of eosinophils in parasitic and allergic inflammation to initiate and sustain an inflammatory response is largely caused by the release of cationic proteins, including MBP (anti–MBP antibody is used to identify eosinophils in tissue sections31 ), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN or EPX). These proteins can directly injure mammalian cells and can induce cytokine and chemokine release from bystander cells. Eosinophils certainly have the capacity to injure the graft, but their importance as effector cells in corneal allograft rejection remains undetermined. That said, of the CD4 cells, CD8 cells, and macrophages that have been consistently found in the infiltrate of rejected grafts,32 33 only CD4 cells have been shown to play an essential role in the rejection process.9 Although graft-infiltrating eosinophils were seen exclusively in allergic conjunctivitis, we found their absolute number to be less than those of CD4 cells, CD8 cells, or macrophages. Further studies are required to ascertain the functional importance of eosinophils as effector cells in graft rejection and whether they contribute to the accelerated rate of rejection seen after perioperative allergic conjunctivitis.
In the model we report, the induced allergy was at its most severe very early in the postoperative course, but this inflammation had far-reaching effects on graft survival. It is possible that the allergen-induced conjunctival inflammation, immediately after transplantation, may influence the afferent and the efferent limb of the allogeneic response. In avascular recipient corneas, the indirect route of alloantigen presentation is thought to be predominant,34 with APCs migrating to the graft from recipient conjunctiva and limbus. It may be that phenotypic or functional alterations in conjunctival APC in allergy alter the afferent component of the rejection response.
In summary, we have shown that allergic conjunctivitis at the time of corneal allotransplantation significantly shortens corneal allograft survival. The increased rate of graft rejection after perioperative allergic conjunctivitis is correlated with an eosinophilic infiltrate of the graft and anterior uvea at the time of rejection, but this may be only one aspect of the allogeneic response to a graft in allergic eye disease in addition to that found in its absence.
| Footnotes |
|---|
Submitted for publication August 16, 2006; revised January 1 and March 23, 2007; accepted July 9, 2007.
Disclosure: T.H. Flynn, None; M. Ohbayashi, None; Y. Ikeda, None; S.J. Ono, None; D.F. Larkin, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Thomas H. Flynn, Department of Ocular Immunology, Institute of Ophthalmology, 11–43 Bath Street, London EC1V 9EL, United Kingdom; t.flynn{at}ucl.ac.uk.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |